Indivior Pharmaceuticals, Inc. (INDV) Stock Price & Analysis

Indivior Pharmaceuticals, Inc. (INDV) closed at USD 35.33 on Thursday, October 22, 2026, up 1.55% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 34.79; the Oct 22, 2026 session ranged USD 34.54–35.36 on volume of 871,671 shares. Market capitalization is $4.17B, with a 52-week range of USD 24.28–42.81 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:06 UTC.

Also available as compact Markdown for AI agents: nexqual.com/INDV.md

Key facts (INDV)

• Last four reported quarters (through Jun 30, 2026): revenue $1.33B, net income $355M (26.7% margin), free cash flow -$111M (SEC filings).
• Valuation: P/E 11.7x (avg 129.0x at the last 2 fiscal year-ends).
• 1 of 80 tracked superinvestors hold INDV (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
• Insider open-market sales, last ~7 months: 3 Form 4 filings, $2.8M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 2 Form 4 filings, $108K; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 49 (range 43–53).
• Total return with dividends: 1Y +39.8% vs S&P 500 +14.9%; 5Y +122.2% vs S&P 500 +80.3%.
• Next earnings: 2026-10-29, EPS estimate USD 1.12, revenue estimate $329M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (INDV)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (INDV)

P/E 11.7x · P/S 3.1x · FCF yield -2.66% · Earnings yield 8.51% · Buyback yield (TTM) 7.24%

P/E at fiscal year-ends: Dec 2025 21.9x, Dec 2024 236.2x.

Superinvestors (SEC 13F-HR, Q2 2026) (INDV)

1 of 80 tracked investors hold INDV. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (INDV)

3 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (INDV)

2 purchases, $108K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (INDV)

Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 49 (low 43, high 53).

Rating changes, last 120 days:

Total return (dividends reinvested) (INDV)

INDV customer concentration

In the period ended Dec 31, 2025, 4 direct customers each accounted for at least 10% (20%, 18%, 13%, 13%) of revenue, per the company's 10-K filed Feb 26, 2026. The company does not name them.

INDV company outlook (results filed Aug 3, 2026)

• “Guidance • Q2'26 Total Net Revenue of $343 Million, Up 14% YoY • Record Quarterly Total SUBLOCADE ®”

Quoted word-for-word from the SEC 8-K results press release.

INDV analyst estimates and revisions

INDV options: expected move

Options price a move of about ±14.4% (±$5.10) by Nov 20, 2026, which includes earnings on Oct 29, 2026. Over the last 6 reports the stock moved ±13.6% on average.

30-day implied volatility 58.7% vs 30.8% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 10:06 UTC)

Technical Analysis (INDV)

Nexqual's technical model rates INDV "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 10:06 UTC.

Analyst Ratings (INDV)

Wall Street analysts rate INDV "Buy" based on 4 analysts, with a mean price target of USD 49 (range USD 43–53), per Nexqual as of October 23, 2026 at 10:06 UTC.

Earnings (INDV)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 10:06 UTC.

Financials & Fundamentals (INDV)

Source: Nexqual, October 23, 2026 at 10:06 UTC.

Financial Health Score (INDV)

Nexqual rates Indivior Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:06 UTC.

Ownership (INDV)

Source: Nexqual, October 23, 2026 at 10:06 UTC.

Leadership (INDV)

Indivior Pharmaceuticals, Inc. is led by Joseph J. Ciaffoni, CEO & Director, per Nexqual as of October 23, 2026 at 10:06 UTC.

Major Backers & Investors (INDV)

Notable institutional backers of Indivior Pharmaceuticals, Inc. include Oaktree Capital Management LP, Fuller & Thaler Asset Management Inc., Two Seas Capital Lp, according to Nexqual as of October 23, 2026 at 10:06 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 10:06 UTC.

From Indivior Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• The FCP manufactures the buprenorphine HCl API used in the manufacture of SUBOXONE Film, SUBUTEX Tablet, and SUBOXONE Tablet, and the buprenorphine base API used in the formulation of SUBLOCADE long-acting injection.
• The distribution of our buprenorphine products is more complicated than other specialty pharmaceutical products because buprenorphine is regulated in the U.S. as a Schedule III drug by the FDA, and similarly restricted by law enforcement authorities in the Rest of World.

Partnerships

• SUBOXONE Film was developed as an alternative to the sublingual tablet through an exclusive agreement with Aquestive (formerly known as Monosol), utilizing its proprietary technology to deliver buprenorphine in a fast-dissolving sublingual film.
• As part of the agreement with the DOJ ("Resolution Agreement"), a wholly owned subsidiary of Indivior PLC pleaded guilty to a single count of making false statements relating to healthcare matters in 2012 in violation of 18 U.S.C.

Legal & Regulatory Risks (Item 1A, quoted)

• Regulatory agencies may impose limitations or post-approval requirements on our products.
• Product liability and product recalls could have a material adverse effect on us.
• We may fail to comply with payment and reporting obligations under governmental pricing programs.
• Failure to comply with anti-corruption laws and regulations, anti-money laundering laws and regulations, and/or economic sanctions could result in us becoming subject to fines or penalties.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:06 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt